187 related articles for article (PubMed ID: 35589447)
1. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.
Goebel GL; Qiu X; Wu P
Trends Pharmacol Sci; 2022 Oct; 43(10):866-881. PubMed ID: 35589447
[TBL] [Abstract][Full Text] [Related]
2. Trends in kinase drug discovery: targets, indications and inhibitor design.
Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
Wu P; Nielsen TE; Clausen MH
Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
[TBL] [Abstract][Full Text] [Related]
4. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Lu X; Smaill JB; Ding K
J Med Chem; 2020 Oct; 63(19):10726-10741. PubMed ID: 32432477
[TBL] [Abstract][Full Text] [Related]
5. FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections.
Meineke R; Stelz S; Busch M; Werlein C; Kühnel M; Jonigk D; Rimmelzwaan GF; Elbahesh H
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146864
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors.
Du J; Yan H; Xu Z; Yang B; He Q; Wang X; Luo P
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1311-1325. PubMed ID: 34743659
[TBL] [Abstract][Full Text] [Related]
7. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
8. An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches.
Li L; Liu S; Wang B; Liu F; Xu S; Li P; Chen Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762253
[TBL] [Abstract][Full Text] [Related]
9. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
10. Perturbation of biological processes with small molecule kinase inhibitors.
Li W; Wang J; Liang R; Lei X
Curr Opin Chem Biol; 2022 Oct; 70():102185. PubMed ID: 35853282
[TBL] [Abstract][Full Text] [Related]
11. Allosteric small-molecule kinase inhibitors.
Wu P; Clausen MH; Nielsen TE
Pharmacol Ther; 2015 Dec; 156():59-68. PubMed ID: 26478442
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors.
Jin Y; Xu Z; Yan H; He Q; Yang X; Luo P
Front Pharmacol; 2020; 11():891. PubMed ID: 32595510
[TBL] [Abstract][Full Text] [Related]
13. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors.
Olaharski AJ; Gonzaludo N; Bitter H; Goldstein D; Kirchner S; Uppal H; Kolaja K
PLoS Comput Biol; 2009 Jul; 5(7):e1000446. PubMed ID: 19629159
[TBL] [Abstract][Full Text] [Related]
14. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
Latham BD; Geffert RM; Jackson KD
Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
[TBL] [Abstract][Full Text] [Related]
15. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy.
Groppe JC
Expert Opin Drug Discov; 2019 Dec; 14(12):1237-1253. PubMed ID: 31513432
[No Abstract] [Full Text] [Related]
16. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
17. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of FDA-approved small molecule kinase inhibitors.
Jiang H; Jin Y; Yan H; Xu Z; Yang B; He Q; Luo P
Expert Opin Drug Saf; 2021 Mar; 20(3):335-348. PubMed ID: 33356646
[No Abstract] [Full Text] [Related]
19. Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.
Zarakas MA; Desai JV; Chamilos G; Lionakis MS
Curr Fungal Infect Rep; 2019 Sep; 13(3):86-98. PubMed ID: 31555394
[TBL] [Abstract][Full Text] [Related]
20. Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
Fasano M; Della Corte CM; Califano R; Capuano A; Troiani T; Martinelli E; Ciardiello F; Morgillo F
Expert Opin Investig Drugs; 2014 Jun; 23(6):809-21. PubMed ID: 24673358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
